PatientsVille.com Logo


Intron Medical Research Studies

Up-to-date List of Intron Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Intron Medical Research Studies

Rank Status Study
1 Recruiting A Study of the Safety and Efficacy of PEG-Intron™ Versus PEGASYS™ in Participants With Chronic Hepatitis B (P08450)
Condition: Hepatitis B, Chronic
Interventions: Biological: PEG-Intron™;   Biological: PEGASYS™
Outcome Measures: Proportion of HBeAg(+) participants achieving HBeAg seroconversion at 24 weeks post-treatment;   Proportion of HBeAg(-) participants achieving hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels <2000 IU/mL at 24 weeks post-treatment;   Proportion of HBeAg(+) participants achieving HBV DNA <2000 IU/mL at 24 weeks post-treatment;   Proportion of HBeAg(+) participants achieving alanine aminotransferase (ALT) normalization at 24 weeks post-treatment;   Proportion of HBeAg(+) participants achieving the combined response of HBeAg seroconversion and HBV DNA <2000 IU/mL at 24 weeks post-treatment;   Proportion of HBeAg(-) participants achieving ALT normalization at 24 weeks post-treatment
2 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Biological: recombinant interferon alfa-2b;   Other: quality-of-life assessment
Outcome Measures: Recurrence-free survival;   Overall survival;   Incidence of toxicity assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Change in global quality of life assessed using the FACT-G;   Change in health-related domains of quality of life assessed using symptom and functioning subscales
3 Recruiting Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients
Condition: Cutaneous Melanoma
Interventions: Biological: CSF470 vaccine, BCG, Molgramostim;   Drug: interferon alpha 2b
Outcome Measures: Efficacy;   security;   Quality of Life;   Induction of immune responses
4 Recruiting Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Biological: recombinant interferon alfa-2b;   Other: laboratory biomarker analysis
Outcome Measures: Progression-free survival;   Regimen limiting serious adverse events (AEs), defined as grade 3 or higher immune mediated AE that require steroids or immunosuppressive therapy according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0;   Overall survival;   Response rate by RECIST and by immune-related response criteria;   PFS for ipilimumab 10 mg/kg treatment in comparison to ipilimumab 3 mg/kg
5 Recruiting Study of PEG-Intron for Plexiform Neurofibromas
Condition: Plexiform Neurofibroma
Intervention: Drug: PEG-Intron
Outcome Measure: The primary outcomes for the the study will be response or progression free survival, depending on the stratum in which the patient has enrolled.
6 Unknown  Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
Conditions: Chronic Hepatitis B;   Chronic Hepatitis D
Intervention: Drug: pegylated IFN alfa-2b plus ribavirin
Outcome Measures: the efficacy of 24-week pegylated IFN alfa-2b plus RBV for SVR of HDV in patients with dual chronic hepatitis D and B;   the efficacy of pegylated IFN alfa-2b plus RBV in patients with dual chronic hepatitis D and B on: The biochemical response rate;   The degree of histologic change
7 Recruiting Adjuvant PEG Intron in Ulcerated Melanoma
Condition: Ulcerated Melanomas
Intervention: Biological: PEG IFN alfa-2b
Outcome Measures: Relapse-free survival (RFS);   Occurence of Adverse Events;   Overall survival (OS);   Distant metastases-free survival (DMFS);   Quality of life
8 Recruiting IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: Ipilimumab;   Drug: Temozolomide;   Drug: Cisplatin;   Drug: Interferon Alfa-2b;   Drug: Interleukin-2
Outcome Measure: Tumor Response by Participant using immune-related response criteria (irRC)
9 Recruiting Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
Condition: Melanoma
Interventions: Drug: High-dose Interferon alfa-2b;   Drug: Vemurafenib
Outcome Measures: Number of Participants with Adverse Events to determine Ph II dose;   Progression Free and overall survival (Efficacy)
10 Not yet recruiting A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
Condition: Melanoma
Intervention: Biological: Pegylated Interferon Alfa-2b
Outcome Measures: Number of participants who experience an adverse event (AE);   Number of participants who discontinue study medication due to an AE
11 Recruiting Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: IL-2;   Drug: Interferon Alpha-2b
Outcome Measures: Maximum Tolerated Dose (MTD);   Progression-Free Survival (PFS)
12 Unknown  PEG-IFN Plus Ribavirin Combination Therapy for Older Patients
Condition: Hepatitis C Virus
Intervention: Drug: Pegylated interferon alpha-2b plus ribavirin
Outcome Measures: antiviral effect by PEG-IFN alpha-2b plus RBV treatment;   the tolerance of older patients by PEG-IFN alpha-2b plus RBV treatment
13 Recruiting Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)
Condition: Hepatitis C, Chronic
Interventions: Drug: PEG-IFN alfa-2b;   Drug: ribavirin
Outcome Measure: Number of Participants Achieving Sustained Virologic Response (SVR)
14 Recruiting Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib, Pegylated interferon alpha-2b, Imatinib
Outcome Measure: level of BCR-ABL
15 Recruiting PegIntron to Treat Plexiform Neurofibromas in Children and Young Adults
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibroma
Intervention: Drug: PEG-interferon alfa-2b
Outcome Measures: Radiographic response (stratum 1);   Radiographic and clinical response (stratum 2);   Progression-free survival (stratum 3);   Clinical and radiographic response (stratum3)
16 Recruiting Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
Condition: Polycythemia Vera
Interventions: Drug: Peg-P-IFN-alpha-2b (AOP2014);   Drug: Hydroxyurea
Outcome Measures: Disease response rate;   Disaese response;   JAK2 allelic burden changes;   time to response;   duration of response;   number of phlebotomies;   blood parameters;   spleen size;   disease related symptoms;   adverse events;   protocol-specific adverse events of special interest
17 Unknown  Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon
Conditions: Adjuvant;   Stage III Malignant Melanoma;   Interferon Alpha;   Therapy
Intervention: Drug: Interferon-alpha-2b
Outcome Measures: distant metastasis free survival/(DMFI );   overall survival;   time to progression;   toxicity
18 Recruiting Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Condition: HIV Infection
Intervention: Drug: Interferon Alpha 2b
Outcome Measures: We will compare viral RNA levels in blood drawn before, during, and after intensification with interferon.;   HIV-1 genetic sequencing will be performed to determine whether interferon therapy results in differences in population structure during the 4-week intensification period.
19 Not yet recruiting Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C
Condition: Hepatitis C, Chronic
Interventions: Drug: Legalon® SIL (Silibinin);   Drug: Pegylated interferon alfa2b;   Drug: Ribavirin
Outcome Measures: Undetectable HCV-RNA at 24 Weeks After the end of the Study Treatment;   Undetectable HCV-RNA;   HCV-RNA decrease ≥ 2 log10 IU/mL;   Normalization of Serum Alanine Aminotransferase;   Number of Participants with adverse events (AEs)
20 Not yet recruiting Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase
Condition: Chronic Phase of Chronic Myeloid Leukemia
Interventions: Drug: Dasatinib;   Drug: Peg-Interferon alpha2b
Outcome Measures: Cumulative rate of molecular response;   Rate of complete cytogenetic response;   Rate of major molecular responses;   Rate of molecular response;   Kinetics and duration;   Rate of PegIFN-α2b and dasatinib discontinuation

These studies may lead to new treatments and are adding insight into Intron etiology and treatment.

A major focus of Intron research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Intron